The Wegovy pill is a new oral weight loss medication containing semaglutide. Learn how it works, its strict dosing rules, and clinical trial results.
The Wegovy pill, now available privately in the UK as of July 2026, delivers the same active ingredient — semaglutide — as the popular injectable version. This GLP-1 receptor agonist works by suppressing appetite, slowing gastric emptying, and improving blood sugar control, leading to clinically meaningful weight loss when combined with diet and exercise.
In clinical trials, oral semaglutide demonstrated weight loss comparable to the injection, with many participants losing 5–10% of their body weight over 68 weeks.
For those who fear needles, the daily pill offers a practical alternative. Yet its convenience is offset by strict dosing requirements that demand careful planning.
Absorption of oral semaglutide is highly dependent on correct administration. The pill must be taken on an empty stomach after at least eight hours of fasting — meaning first thing in the morning is ideal for most patients.
Swallow the tablet whole with a sip of up to 120ml of plain water only — no fizzy drinks, coffee, or tea — and wait at least 30 minutes before eating, drinking, or taking any other medications.
These strict rules can be challenging for those with irregular schedules, but they are non-negotiable for achieving full efficacy.
Clinical trials for oral semaglutide mirrored the outcomes of the injection. Over 68 weeks, participants experienced an average weight loss of 5–15%, with a significant proportion achieving reductions of 10% or more. The results solidify the pill as a viable first‑line pharmacological option for obesity.
Side effects reflect the GLP-1 class: nausea, vomiting, diarrhea, and constipation are most common. These often lessen with gradual dose escalation and strict adherence to the fasting and hydration guidelines. The pill is now available privately at a cost of approximately £200–300 per month, but it is not yet covered by the NHS.
As with the injection, long‑term weight management requires sustained use; discontinuation often leads to regain. Patients must weigh the cost and commitment against the potential health benefits.